Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios A Dimopoulos

Showing results (171-180 of 740) with videos related to

Pageof 74
Sort By:
International Journal of Dentistry|July 22, 2014
Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patientsPelagia I Melea, Ioannis Melakopoulos, Efstathios Kastritis, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2015
Risk Factors for Multiple Myeloma: A Systematic Review of Meta-AnalysesTheodoros N Sergentanis, Flora Zagouri, Gerasimos Tsilimidos, et al.
International Journal of Cancer|January 8, 2019
Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studiesTheodora Psaltopoulou, Theodoros N Sergentanis, Ioannis Ntanasis-Stathopoulos, et al.
Critical Reviews in Oncology/Hematology|September 14, 2010
Developments in the systemic treatment of endometrial cancerGiannis Mountzios, Dimitrios Pectasides, Evangelos Bournakis, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 18, 2019
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone DiseaseAnastasios Kyriazoglou, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
Gynecologic Oncology|October 21, 2006
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinomaGeorge Bozas, Aristotle Bamias, Vassiliki Koutsoukou, et al.
Obstetrics and Gynecology International|February 12, 2010
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Flora Zagouri, George Bozas, Eftichia Kafantari, et al.
Leukemia & Lymphoma|March 23, 2002
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology GroupMeletios A Dimopoulos, George Fountzilas, Efstathios Papageorgiou, et al.
European Journal of Haematology|July 9, 2013
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
Pageof 74

Showing results (171-180 of 740) with videos related to

Sort By:
Pageof 74
International Journal of Dentistry|July 22, 2014
Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patientsPelagia I Melea, Ioannis Melakopoulos, Efstathios Kastritis, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2015
Risk Factors for Multiple Myeloma: A Systematic Review of Meta-AnalysesTheodoros N Sergentanis, Flora Zagouri, Gerasimos Tsilimidos, et al.
International Journal of Cancer|January 8, 2019
Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studiesTheodora Psaltopoulou, Theodoros N Sergentanis, Ioannis Ntanasis-Stathopoulos, et al.
Critical Reviews in Oncology/Hematology|September 14, 2010
Developments in the systemic treatment of endometrial cancerGiannis Mountzios, Dimitrios Pectasides, Evangelos Bournakis, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 18, 2019
Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone DiseaseAnastasios Kyriazoglou, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, et al.
Future Oncology (London, England)|December 14, 2019
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study designPhilippe Moreau, Meletios A Dimopoulos, Kwee Yong, et al.
Gynecologic Oncology|October 21, 2006
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinomaGeorge Bozas, Aristotle Bamias, Vassiliki Koutsoukou, et al.
Obstetrics and Gynecology International|February 12, 2010
Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Flora Zagouri, George Bozas, Eftichia Kafantari, et al.
Leukemia & Lymphoma|March 23, 2002
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology GroupMeletios A Dimopoulos, George Fountzilas, Efstathios Papageorgiou, et al.
European Journal of Haematology|July 9, 2013
The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?Evangelos Terpos, Dimitrios Christoulas, Efstathios Kastritis, et al.
Pageof 74